# Skeptic's Evaluation of Mechanistically-Specific Tau PTM Hypotheses
---
## Hypothesis 1: K280 Acetylation as Aggregation Nucleation Site
### Strongest Specific Weakness
**Mechanistic claim exceeds structural evidence.** The assertion that K280 acetylation creates a "β-sheet nucleation interface" implies a defined conformational change, yet no atomic-resolution structure of acetylated tau exists showing how this modification templated aggregation. The proposed mechanism conflates *correlation* (K280 acetylation correlates with disease) with *causation* (acetylation drives nucleation). Without a structural model of how the acetyl-lysine side chain at position 280 alters tau's prion-like propagation geometry, the "nucleation interface" remains a Black Box.
### Counter-Evidence & Complications
1. **Reversibility problem:** Acetyltransferases and deacetylases (especially SIRT1) dynamically regulate K280 acetylation. If acetylation truly creates a stable "seeding template," how does the system maintain substrate specificity when deacetylation can reverse the modification within hours? The prion model requires templated propagation—acetylation's reversibility argues against stable conformational templating.
2. **p300/CBP are pleiotropic with limited selectivity:** p300/CBP have ~2,000 known protein substrates (Wang et al., Nature 2013, PMID: 23927689). Pan-acetyltransferase inhibition would affect histone acetylation (gene regulation), metabolic enzymes, and cytoskeletal proteins. The therapeutic window for systemic p300/CBP inhibition is therefore narrow—this is not a selective tau-targeting approach.
3. **K280 acetylation is not uniquely AD-specific:** Literature suggests K280 acetylation can occur in contexts beyond AD, including aging and other neurodegenerative conditions (Cohen et al. follow-up studies). If it's present in non-disease states, its specificity as a "defining pathogenic event" is weakened.
4. **Phosphorylation remains dominant:** Tau's aggregation is most robustly seeded by phosphorylated tau (hyperphosphorylated at AT8 and AT100 epitopes). Acetylation may be a secondary modification that facilitates but doesn't define primary pathogenicity.
### Pointed Question
**Given that p300/CBP inhibition would affect thousands of substrates systemically, what evidence supports the claim that selective targeting of neuronal p300/CBP-mediated tau acetylation in the entorhinal cortex would achieve therapeutic benefit without disrupting critical hippocampal memory consolidation processes that also depend on histone acetylation?** Specifically, CBP is essential for consolidation of fear memory (Alarcón et al., 2002), and p300/CBP inhibitors have failed in cancer trials partly due to CNS side effects.
### Confidence Rating: **MODERATE (overstated)**
The hypothesis has genuine mechanistic plausibility and solid foundational papers (Cohen, Cook). However, the disease-specificity claim is overstated given evidence of K280 acetylation in non-AD conditions, and the therapeutic targeting strategy via p300/CBP inhibition carries massive selectivity problems. The falsifiability criterion is met (the K280R prediction is testable), but the mechanistic framework linking acetylation to stable templated aggregation needs structural support.
---
## Hypothesis 2: Caspase-6 Cleavage at D421 (Truncated)
*Note: The hypothesis text was incomplete. I'll evaluate based on the title and standard mechanistic framework for this modification.*
### Strongest Specific Weakness
**Caspase-6 activation may be a consequence, not a driver, of tau pathology.** The field has struggled to establish whether caspase-6 cleavage of tau is upstream or downstream of neurodegeneration. If tau aggregation itself triggers caspase-6 activation as a secondary event (e.g., through mitochondrial dysfunction and apoptosis signaling), then D421 cleavage is a *marker* of dying neurons, not a driver of spreading. Blocking caspase-6 cleavage would therefore not halt disease progression—it would merely prevent a downstream executional event.
### Counter-Evidence & Complications
1. **Caspase-6 is an executioner caspase—causality vs. executional role:** In classic apoptosis,